Depczynski Barbara, Poynten Ann
Prince of Wales Hospital, Randwick, Australia.
JMIR Diabetes. 2022 May 9;7(2):e35163. doi: 10.2196/35163.
Continuous glucose monitors (CGM) can provide detailed information on glucose excursions. There is little information on safe transitioning from hospital back to the community for patients who have had diabetes therapies adjusted in hospital and it is unclear whether newer technologies may facilitate this process.
Our aim was to determine whether offering CGM on discharge would be acceptable and if CGM initiated on hospital discharge in people with type 2 diabetes (T2DM) would reduce hospital re-presentations at 1 month.
This was an open-label study. Adult inpatients with T2DM, who were to be discharged home and required postdischarge glycemic stabilization, were offered usual care consisting of clinic review at 2 weeks and at 3 months. In addition to usual care, participants in the intervention arm were provided with a Libre flash glucose monitoring system (Abbott Australia). An initial run-in phase for the first 20 participants was planned, where all consenting participants were enrolled in an active arm. Subsequently, all participants were to be randomized to the active arm or usual care control group.
Of 237 patients screened during their hospital admission, 34 had comorbidities affecting cognition that prevented informed consent and affected their ability to learn to use the CGM device. In addition, 21 were not able to be approached as the material was only in English. Of 101 potential participants who fulfilled eligibility criteria, 19 provided consent and were enrolled. Of the 82 patients who declined to participate, 31 advised that the learning of a new task toward discharge was overwhelming or too stressful and 26 were not interested, with no other details. Due to poor recruitment, the study was terminated without entering the randomization phase to determine whether CGM could reduce readmission rate.
These results suggest successful and equitable implementation of telemedicine programs requires that any human factors such as language, cognition, and possible disengagement be addressed. Recovery from acute illness may not be the ideal time for introduction of newer technologies or may require more novel implementation frameworks.
连续血糖监测仪(CGM)可提供有关血糖波动的详细信息。对于在医院调整过糖尿病治疗方案的患者,关于其从医院安全过渡回社区的信息很少,而且尚不清楚新技术是否有助于这一过程。
我们的目的是确定出院时提供CGM是否可接受,以及2型糖尿病(T2DM)患者出院时启动CGM是否会降低1个月内再次入院的几率。
这是一项开放标签研究。成年T2DM住院患者,若将出院回家且出院后需要血糖稳定,将接受常规护理,包括在2周和3个月时进行门诊复查。除常规护理外,干预组的参与者还获得了一个Libre闪光血糖监测系统(雅培澳大利亚公司)。计划对前20名参与者进行初始磨合阶段,所有同意参与的参与者都被纳入积极干预组。随后,所有参与者将被随机分配到积极干预组或常规护理对照组。
在入院期间筛查的237名患者中,34名患有影响认知的合并症,这妨碍了知情同意并影响了他们学习使用CGM设备的能力。此外,由于材料仅为英文,有21名患者无法联系。在101名符合资格标准的潜在参与者中,19名提供了同意并被纳入研究。在82名拒绝参与的患者中,31名表示临近出院时学习一项新任务压力过大,26名不感兴趣,未提供其他细节。由于招募情况不佳,该研究在未进入随机化阶段以确定CGM是否能降低再入院率的情况下终止。
这些结果表明,远程医疗项目的成功和公平实施需要解决诸如语言、认知和可能的脱离接触等人为因素。从急性疾病中恢复可能不是引入新技术的理想时机,或者可能需要更新颖的实施框架。